Molecular subtyping of tumors from patients with familial glioma

Vanessa Y. Ruiz, Corinne E. Praska, Georgina Armstrong, Thomas M. Kollmeyer, Seiji Yamada, Paul A. Decker, Matthew L. Kosel, Jeanette E Eckel-Passow, Daniel H Lachance, Matthew N. Bainbridge, Beatrice S. Melin, Melissa L. Bondy, Robert Brian Jenkins

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background Single-gene mutation syndromes account for some familial glioma (FG); however, they make up only a small fraction of glioma families. Gliomas can be classified into 3 major molecular subtypes based on isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion. We hypothesized that the prevalence of molecular subtypes might differ in familial versus sporadic gliomas and that tumors in the same family should have the same molecular subtype. Methods Participants in the FG study (Gliogene) provided samples for germline DNA analysis. Formalin-fixed, paraffin-embedded tumors were obtained from a subset of FG cases, and DNA was extracted. We analyzed tissue from 75 families, including 10 families containing a second affected family member. Copy number variation data were obtained using a first-generation Affymetrix molecular inversion probe (MIP) array. Results Samples from 62 of 75 (83%) FG cases could be classified into the 3 subtypes. The prevalence of the molecular subtypes was: 30 (48%) IDH-wildtype, 21 (34%) IDH-mutant non-codeleted, and 11 (19%) IDH-mutant and 1p/19q codeleted. This distribution of molecular subtypes was not statistically different from that of sporadic gliomas (P = 0.54). Of 10 paired FG samples, molecular subtypes were concordant for 7 (κ = 0.59): 3 IDH-mutant non-codeleted, 2 IDH-wildtype, and 2 IDH-mutant and 1p/19q codeleted gliomas. Conclusions Our data suggest that within individual families, patients develop gliomas of the same molecular subtype. However, we did not observe differences in the prevalence of the molecular subtypes in FG compared with sporadic gliomas. These observations provide further insight into the distribution of molecular subtypes in FG.

Original languageEnglish (US)
Pages (from-to)810-817
Number of pages8
JournalNeuro-Oncology
Volume20
Issue number6
DOIs
StatePublished - May 18 2018

Fingerprint

Glioma
Isocitrate Dehydrogenase
Neoplasms
Molecular Probes
Mutation
DNA
Paraffin
Formaldehyde

Keywords

  • familial glioma (FG)
  • IDH -mutant and 1p/19q-codeleted
  • IDH -mutant non-codeleted
  • IDH -wild type
  • molecular inversion probe (MIP)

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Ruiz, V. Y., Praska, C. E., Armstrong, G., Kollmeyer, T. M., Yamada, S., Decker, P. A., ... Jenkins, R. B. (2018). Molecular subtyping of tumors from patients with familial glioma. Neuro-Oncology, 20(6), 810-817. https://doi.org/10.1093/neuonc/nox192

Molecular subtyping of tumors from patients with familial glioma. / Ruiz, Vanessa Y.; Praska, Corinne E.; Armstrong, Georgina; Kollmeyer, Thomas M.; Yamada, Seiji; Decker, Paul A.; Kosel, Matthew L.; Eckel-Passow, Jeanette E; Lachance, Daniel H; Bainbridge, Matthew N.; Melin, Beatrice S.; Bondy, Melissa L.; Jenkins, Robert Brian.

In: Neuro-Oncology, Vol. 20, No. 6, 18.05.2018, p. 810-817.

Research output: Contribution to journalArticle

Ruiz, VY, Praska, CE, Armstrong, G, Kollmeyer, TM, Yamada, S, Decker, PA, Kosel, ML, Eckel-Passow, JE, Lachance, DH, Bainbridge, MN, Melin, BS, Bondy, ML & Jenkins, RB 2018, 'Molecular subtyping of tumors from patients with familial glioma', Neuro-Oncology, vol. 20, no. 6, pp. 810-817. https://doi.org/10.1093/neuonc/nox192
Ruiz VY, Praska CE, Armstrong G, Kollmeyer TM, Yamada S, Decker PA et al. Molecular subtyping of tumors from patients with familial glioma. Neuro-Oncology. 2018 May 18;20(6):810-817. https://doi.org/10.1093/neuonc/nox192
Ruiz, Vanessa Y. ; Praska, Corinne E. ; Armstrong, Georgina ; Kollmeyer, Thomas M. ; Yamada, Seiji ; Decker, Paul A. ; Kosel, Matthew L. ; Eckel-Passow, Jeanette E ; Lachance, Daniel H ; Bainbridge, Matthew N. ; Melin, Beatrice S. ; Bondy, Melissa L. ; Jenkins, Robert Brian. / Molecular subtyping of tumors from patients with familial glioma. In: Neuro-Oncology. 2018 ; Vol. 20, No. 6. pp. 810-817.
@article{f9cbe7b96268431fb6d16e63905ac72f,
title = "Molecular subtyping of tumors from patients with familial glioma",
abstract = "Background Single-gene mutation syndromes account for some familial glioma (FG); however, they make up only a small fraction of glioma families. Gliomas can be classified into 3 major molecular subtypes based on isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion. We hypothesized that the prevalence of molecular subtypes might differ in familial versus sporadic gliomas and that tumors in the same family should have the same molecular subtype. Methods Participants in the FG study (Gliogene) provided samples for germline DNA analysis. Formalin-fixed, paraffin-embedded tumors were obtained from a subset of FG cases, and DNA was extracted. We analyzed tissue from 75 families, including 10 families containing a second affected family member. Copy number variation data were obtained using a first-generation Affymetrix molecular inversion probe (MIP) array. Results Samples from 62 of 75 (83{\%}) FG cases could be classified into the 3 subtypes. The prevalence of the molecular subtypes was: 30 (48{\%}) IDH-wildtype, 21 (34{\%}) IDH-mutant non-codeleted, and 11 (19{\%}) IDH-mutant and 1p/19q codeleted. This distribution of molecular subtypes was not statistically different from that of sporadic gliomas (P = 0.54). Of 10 paired FG samples, molecular subtypes were concordant for 7 (κ = 0.59): 3 IDH-mutant non-codeleted, 2 IDH-wildtype, and 2 IDH-mutant and 1p/19q codeleted gliomas. Conclusions Our data suggest that within individual families, patients develop gliomas of the same molecular subtype. However, we did not observe differences in the prevalence of the molecular subtypes in FG compared with sporadic gliomas. These observations provide further insight into the distribution of molecular subtypes in FG.",
keywords = "familial glioma (FG), IDH -mutant and 1p/19q-codeleted, IDH -mutant non-codeleted, IDH -wild type, molecular inversion probe (MIP)",
author = "Ruiz, {Vanessa Y.} and Praska, {Corinne E.} and Georgina Armstrong and Kollmeyer, {Thomas M.} and Seiji Yamada and Decker, {Paul A.} and Kosel, {Matthew L.} and Eckel-Passow, {Jeanette E} and Lachance, {Daniel H} and Bainbridge, {Matthew N.} and Melin, {Beatrice S.} and Bondy, {Melissa L.} and Jenkins, {Robert Brian}",
year = "2018",
month = "5",
day = "18",
doi = "10.1093/neuonc/nox192",
language = "English (US)",
volume = "20",
pages = "810--817",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Molecular subtyping of tumors from patients with familial glioma

AU - Ruiz, Vanessa Y.

AU - Praska, Corinne E.

AU - Armstrong, Georgina

AU - Kollmeyer, Thomas M.

AU - Yamada, Seiji

AU - Decker, Paul A.

AU - Kosel, Matthew L.

AU - Eckel-Passow, Jeanette E

AU - Lachance, Daniel H

AU - Bainbridge, Matthew N.

AU - Melin, Beatrice S.

AU - Bondy, Melissa L.

AU - Jenkins, Robert Brian

PY - 2018/5/18

Y1 - 2018/5/18

N2 - Background Single-gene mutation syndromes account for some familial glioma (FG); however, they make up only a small fraction of glioma families. Gliomas can be classified into 3 major molecular subtypes based on isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion. We hypothesized that the prevalence of molecular subtypes might differ in familial versus sporadic gliomas and that tumors in the same family should have the same molecular subtype. Methods Participants in the FG study (Gliogene) provided samples for germline DNA analysis. Formalin-fixed, paraffin-embedded tumors were obtained from a subset of FG cases, and DNA was extracted. We analyzed tissue from 75 families, including 10 families containing a second affected family member. Copy number variation data were obtained using a first-generation Affymetrix molecular inversion probe (MIP) array. Results Samples from 62 of 75 (83%) FG cases could be classified into the 3 subtypes. The prevalence of the molecular subtypes was: 30 (48%) IDH-wildtype, 21 (34%) IDH-mutant non-codeleted, and 11 (19%) IDH-mutant and 1p/19q codeleted. This distribution of molecular subtypes was not statistically different from that of sporadic gliomas (P = 0.54). Of 10 paired FG samples, molecular subtypes were concordant for 7 (κ = 0.59): 3 IDH-mutant non-codeleted, 2 IDH-wildtype, and 2 IDH-mutant and 1p/19q codeleted gliomas. Conclusions Our data suggest that within individual families, patients develop gliomas of the same molecular subtype. However, we did not observe differences in the prevalence of the molecular subtypes in FG compared with sporadic gliomas. These observations provide further insight into the distribution of molecular subtypes in FG.

AB - Background Single-gene mutation syndromes account for some familial glioma (FG); however, they make up only a small fraction of glioma families. Gliomas can be classified into 3 major molecular subtypes based on isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion. We hypothesized that the prevalence of molecular subtypes might differ in familial versus sporadic gliomas and that tumors in the same family should have the same molecular subtype. Methods Participants in the FG study (Gliogene) provided samples for germline DNA analysis. Formalin-fixed, paraffin-embedded tumors were obtained from a subset of FG cases, and DNA was extracted. We analyzed tissue from 75 families, including 10 families containing a second affected family member. Copy number variation data were obtained using a first-generation Affymetrix molecular inversion probe (MIP) array. Results Samples from 62 of 75 (83%) FG cases could be classified into the 3 subtypes. The prevalence of the molecular subtypes was: 30 (48%) IDH-wildtype, 21 (34%) IDH-mutant non-codeleted, and 11 (19%) IDH-mutant and 1p/19q codeleted. This distribution of molecular subtypes was not statistically different from that of sporadic gliomas (P = 0.54). Of 10 paired FG samples, molecular subtypes were concordant for 7 (κ = 0.59): 3 IDH-mutant non-codeleted, 2 IDH-wildtype, and 2 IDH-mutant and 1p/19q codeleted gliomas. Conclusions Our data suggest that within individual families, patients develop gliomas of the same molecular subtype. However, we did not observe differences in the prevalence of the molecular subtypes in FG compared with sporadic gliomas. These observations provide further insight into the distribution of molecular subtypes in FG.

KW - familial glioma (FG)

KW - IDH -mutant and 1p/19q-codeleted

KW - IDH -mutant non-codeleted

KW - IDH -wild type

KW - molecular inversion probe (MIP)

UR - http://www.scopus.com/inward/record.url?scp=85047765948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047765948&partnerID=8YFLogxK

U2 - 10.1093/neuonc/nox192

DO - 10.1093/neuonc/nox192

M3 - Article

VL - 20

SP - 810

EP - 817

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 6

ER -